Compare · CDIO vs IDXX
CDIO vs IDXX
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and IDEXX Laboratories Inc. (IDXX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and IDXX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $43.11B, about 8276.1x CDIO ($5.2M).
- Both names hit the wire about 4 times in the past 4 weeks.
- IDXX has more recent analyst coverage (25 ratings vs 0 for CDIO).
- Company
- Cardio Diagnostics Holdings Inc.
- IDEXX Laboratories Inc.
- Price
- -
- -
- Market cap
- $5.2M
- $43.11B
- 1M return
- -
- +10.63%
- 1Y return
- -
- -11.79%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 1991
- News (4w)
- 4
- 4
- Recent ratings
- 0
- 25
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest CDIO
- SEC Form 4 filed by Director Betts Wendy J
- SEC Form 4 filed by Director Fung Peter K
- SEC Form 4 filed by Director Intrater James
- SEC Form 4 filed by Director Burton Paul Frederick
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
Latest IDXX
- Goldman initiated coverage on IDEXX Labs with a new price target
- KeyBanc Capital Markets initiated coverage on IDEXX Labs
- IDEXX Laboratories to Release 2026 Third Quarter Financial Results
- Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
- IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
- IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
- Director Kingsley Lawrence D exercised 2,203 shares at a strike of $114.17 and sold $1,172,178 worth of shares (2,203 units at $532.08) (SEC Form 4)
- IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- EVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test